They will be available “in time for the autumn booster vaccination campaigns”, they have advanced from BioNTech
August 8, 2022. 3:58 pm
The omicron-adapted vaccine from Pfizer and BioNTech will arrive in October. The BioNTech company announced this Monday that its vaccine against COVID-19 developed together with Pfizer, adapted to the BA.1 and BA.4/5 variants will not arrive until October 2022. They will be available “in time for the autumn booster vaccination campaigns”, they have advanced from BioNTech.
This pharmaceutical company has celebrated the presentation of its financial results for the first half of 2022. These include revenues in the second quarter of 2022 of 3,200 million euros, with a net profit of 1,700 million euros. Revenue for the first half of 2022 amounted to €9.6 billion, with a net profit of €5.4 billion.
Specifically about your vaccine against COVID-19, its forecast is to enter between 13,000 and 17,000 million euros in 2022. This revenue estimate reflects anticipated revenue related to BioNTech’s share of gross profit from sales of the vaccine in the territories of collaborating partners, from direct sales of the vaccine to customers in BioNTech’s territory, and from revenues forecasts generated by products manufactured by BioNTech and sold to collaborating partners.
“In the first half of 2022, we have further strengthened our vaccine leadership and expanded our broad product portfolio. Our vaccine product portfolio COVID-19 includes variant-adapted and next-generation vaccine candidates aimed at long-term and broad protection.”
Advances in Oncology
In Oncology, the company has presented data updates for the individualized mRNA cancer vaccine candidate BNT122 in pancreatic cancer and the novel CAR-T cell therapy candidate BNT211 in solid tumors. This has been the first PRIME designation by the EMA. This has been emphasized Ugur Sahin, CEO and co-founder of BioNTech. “We are moving towards preparing for registration trials, as well as delivering our first BioNTainers in Africa, with the aim of providing access to novel medicines,” added Sahin.
Jens Holstein, CFO of BioNTech, has shown its satisfaction with the results obtained. “We are on track to meet our financial guidance for the current financial year. With our variant-adapted COVID-19 vaccines, we expect increased demand in the fourth quarter of 2022. We will invest in research and development this year and beyond.” We also remain focused on growing our oncology product portfolio as well as furthering our leadership in COVID-19 vaccine development We are driving the potential launch of multiple innovative products to address diseases with high unmet medical need in the next three five years,” he said.